ARS Pharmaceuticals Appoints Donn Casale to Lead Neffy Expansion and CSU Entry
ARS Pharmaceuticals named Donn Casale, a 25-year commercial leader who scaled HEPLISAV-B to over $300 million annual revenue and 50% U.S. market share, as President effective June 1, 2026. He will oversee global commercial operations to accelerate adoption of epinephrine nasal spray neffy and drive expansion into chronic spontaneous urticaria.
1. Leadership Appointment
ARS Pharmaceuticals will have Donn Casale assume the role of President on June 1, 2026, while Richard Lowenthal remains Chief Executive Officer. Casale’s remit includes oversight of global commercial operations and the infrastructure needed to support the company’s next phase of growth.
2. Casale's Commercial Track Record
Casale brings 25 years of biopharmaceutical experience, most recently as Chief Commercial Officer at Dynavax Technologies, where he built U.S. infrastructure for HEPLISAV-B and grew it to more than $300 million in annualized revenue and over 50% U.S. market share. He previously held leadership roles at Depomed and spent 14 years at Merck across sales and commercial strategy.
3. Implications for Neffy and CSU Growth
In his new role, Casale will focus on accelerating patient access and adoption of neffy, the first needle-free epinephrine nasal spray in the U.S., through retail channel execution and payor access strategies. His appointment also signals ARS’s preparation for entry into the chronic spontaneous urticaria market as part of its broader commercial expansion.